Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics and therapeutics of hemoglobinopathies.

Hemoglobin - 1 Jan 2008

Patrinos George P, Grosveld Frank G

Abstract excerpt

Individual genetic constitution is an important cause of variations in the response and tolerance to drug treatment. Single nucleotide polymorphisms (SNPs) in genes located within as well as outside the human beta-globin cluster have recently been shown to be significantly associated with Hb F increase in relation to hydroxyurea (HU) treatment in hemoglobinopathies patients. This article provides an update and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Butyrates
Share to Decitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Hemoglobin

Share to Genome, Human

Share to Hemoglobinopathies

Share to Hydroxyurea

Share to Pharmacogenetics

Source

Identifiers

PMID: 18275000
DOI: 10.1080/03630260701680367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics and therapeutics of hemoglobinopathies.PMID 18275000Read ↗

Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.Semantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

Dissecting the role of genetic modifiers of hemoglobinopathies: A futuristic approach towards precision medicineSemantic proximity Read ↗

Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Semantic proximity Read ↗

Significance of genetic modifiers of hemoglobinopathies leading towards precision medicine.Semantic proximity Read ↗

Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolismSemantic proximity Read ↗

Gene polymorphisms predicting response to hydroxyurea treatment in Bahraini patients with sickle cell disease.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical ManagementSemantic proximity Read ↗

Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical ApplicationsSemantic proximity Read ↗

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell DiseaseSemantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.